Company intelligence / Profile preview
Sinovac Dalian
Dalian, Liaoning, China
- Ownership
- Private
- Employees
- ~531
- Development stage
- Other
01
Overview
Sinovac Dalian has successfully commercialized live-attenuated vaccines for mumps and varicella. Clinical trials for its varicella vaccine demonstrated 87.1% efficacy against any varicella infection and 100% efficacy against moderate-to-severe cases. The company also produces components and manages packaging for the CoronaVac COVID-19 vaccine, which has received WHO emergency use listing.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineLive attenuated vaccineInactivated vaccine
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Dalian Jingang Group
Beyond the preview
Go deeper on Sinovac Dalian.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sinovac Dalian.